BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26848172)

  • 1. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
    Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
    J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
    J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager
    Waaijer SJH; Warnders FJ; Stienen S; Friedrich M; Sternjak A; Cheung HK; van Scheltinga AGTT; Schröder CP; de Vries EGE; Lub-de Hooge MN
    Clin Cancer Res; 2018 Oct; 24(20):4988-4996. PubMed ID: 29980531
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
    Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
    ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
    Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of
    Warnders FJ; Terwisscha van Scheltinga AGT; Knuehl C; van Roy M; de Vries EFJ; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
    J Nucl Med; 2017 Aug; 58(8):1210-1215. PubMed ID: 28360206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.
    Oude Munnink TH; Tamas KR; Lub-de Hooge MN; Vedelaar SR; Timmer-Bosscha H; Walenkamp AM; Weidner KM; Herting F; Tessier J; de Vries EG
    J Nucl Med; 2013 Jun; 54(6):929-35. PubMed ID: 23625582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
    Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
    J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
    Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
    Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.
    Hall MA; Pinkston KL; Wilganowski N; Robinson H; Ghosh P; Azhdarinia A; Vazquez-Arreguin K; Kolonin AM; Harvey BR; Sevick-Muraca EM
    J Nucl Med; 2012 Sep; 53(9):1427-37. PubMed ID: 22872743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
    van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
    J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
    Terwisscha van Scheltinga AG; Lub-de Hooge MN; Hinner MJ; Verheijen RB; Allersdorfer A; Hülsmeyer M; Nagengast WB; Schröder CP; Kosterink JG; de Vries EG; Audoly L; Olwill SA
    J Nucl Med; 2014 Apr; 55(4):665-71. PubMed ID: 24614223
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.